Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Immunologic Deficiency Syndromes | 50 | 2022 | 59 | 14.520 |
Why?
|
DiGeorge Syndrome | 35 | 2023 | 41 | 12.600 |
Why?
|
Lupus Erythematosus, Systemic | 16 | 2023 | 151 | 6.960 |
Why?
|
Common Variable Immunodeficiency | 23 | 2023 | 27 | 5.530 |
Why?
|
T-Lymphocytes | 26 | 2021 | 341 | 5.490 |
Why?
|
Hematopoietic Stem Cell Transplantation | 29 | 2023 | 47 | 5.380 |
Why?
|
Inflammatory Bowel Diseases | 17 | 2022 | 85 | 5.080 |
Why?
|
Monocytes | 16 | 2021 | 258 | 4.570 |
Why?
|
Child | 105 | 2023 | 2875 | 4.560 |
Why?
|
Humans | 285 | 2024 | 34853 | 4.470 |
Why?
|
Chromosomes, Human, Pair 22 | 18 | 2020 | 36 | 4.320 |
Why?
|
B-Lymphocytes | 20 | 2021 | 181 | 4.140 |
Why?
|
Rubella virus | 9 | 2024 | 10 | 3.990 |
Why?
|
Child, Preschool | 75 | 2023 | 1318 | 3.960 |
Why?
|
Chromosome Deletion | 20 | 2023 | 52 | 3.590 |
Why?
|
Influenza, Human | 11 | 2013 | 79 | 3.500 |
Why?
|
Granuloma | 9 | 2022 | 23 | 3.470 |
Why?
|
Severe Combined Immunodeficiency | 13 | 2023 | 14 | 3.470 |
Why?
|
Genetic Diseases, X-Linked | 10 | 2023 | 15 | 3.200 |
Why?
|
Rubella | 7 | 2022 | 13 | 3.180 |
Why?
|
Agammaglobulinemia | 12 | 2023 | 14 | 3.140 |
Why?
|
Influenza Vaccines | 10 | 2013 | 50 | 3.110 |
Why?
|
Autoimmune Diseases | 16 | 2021 | 55 | 3.100 |
Why?
|
Inflammation | 16 | 2022 | 577 | 3.040 |
Why?
|
Infant | 57 | 2023 | 1014 | 3.020 |
Why?
|
Lymphopenia | 6 | 2022 | 15 | 3.000 |
Why?
|
Chromatin | 9 | 2021 | 164 | 2.920 |
Why?
|
Adolescent | 84 | 2023 | 5035 | 2.770 |
Why?
|
Male | 133 | 2023 | 18870 | 2.610 |
Why?
|
Autoimmunity | 16 | 2022 | 52 | 2.600 |
Why?
|
Female | 129 | 2023 | 19873 | 2.580 |
Why?
|
Histones | 10 | 2021 | 177 | 2.470 |
Why?
|
Tumor Necrosis Factor-alpha | 13 | 2021 | 325 | 2.410 |
Why?
|
Phenotype | 26 | 2022 | 650 | 2.340 |
Why?
|
Granulomatous Disease, Chronic | 10 | 2022 | 10 | 2.320 |
Why?
|
Interferon Regulatory Factor-1 | 5 | 2019 | 6 | 2.310 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 6 | 2023 | 10 | 2.290 |
Why?
|
Genetic Predisposition to Disease | 17 | 2021 | 528 | 2.180 |
Why?
|
RNA-Binding Proteins | 7 | 2020 | 145 | 2.160 |
Why?
|
Gene Expression Regulation | 13 | 2021 | 968 | 2.040 |
Why?
|
Registries | 24 | 2023 | 330 | 2.000 |
Why?
|
Lipopolysaccharides | 7 | 2020 | 200 | 1.990 |
Why?
|
Young Adult | 43 | 2023 | 4012 | 1.810 |
Why?
|
Adult | 80 | 2023 | 11034 | 1.800 |
Why?
|
Lupus Nephritis | 4 | 2023 | 22 | 1.790 |
Why?
|
Macrophages | 8 | 2021 | 431 | 1.760 |
Why?
|
Complement System Proteins | 4 | 2022 | 21 | 1.730 |
Why?
|
Infant, Newborn | 35 | 2023 | 871 | 1.730 |
Why?
|
Lymphoproliferative Disorders | 6 | 2023 | 10 | 1.710 |
Why?
|
Immune System Diseases | 8 | 2022 | 20 | 1.640 |
Why?
|
Allergy and Immunology | 4 | 2017 | 11 | 1.640 |
Why?
|
Thymus Gland | 3 | 2020 | 77 | 1.620 |
Why?
|
CD4-Positive T-Lymphocytes | 4 | 2021 | 251 | 1.610 |
Why?
|
Diagnosis, Differential | 21 | 2023 | 211 | 1.560 |
Why?
|
Promoter Regions, Genetic | 13 | 2018 | 484 | 1.550 |
Why?
|
Immunity | 6 | 2021 | 51 | 1.540 |
Why?
|
Cytokines | 11 | 2021 | 569 | 1.510 |
Why?
|
Autoantibodies | 5 | 2018 | 103 | 1.450 |
Why?
|
E1A-Associated p300 Protein | 2 | 2020 | 9 | 1.420 |
Why?
|
Transcription, Genetic | 4 | 2021 | 550 | 1.410 |
Why?
|
Self Disclosure | 4 | 2010 | 42 | 1.360 |
Why?
|
Neonatal Screening | 8 | 2023 | 26 | 1.360 |
Why?
|
Age of Onset | 11 | 2022 | 98 | 1.340 |
Why?
|
Genetic Variation | 3 | 2021 | 328 | 1.330 |
Why?
|
Neutropenia | 4 | 2022 | 18 | 1.330 |
Why?
|
Crohn Disease | 4 | 2021 | 55 | 1.320 |
Why?
|
Retrospective Studies | 29 | 2023 | 1961 | 1.310 |
Why?
|
Sequence Deletion | 2 | 2019 | 87 | 1.300 |
Why?
|
Disease Susceptibility | 7 | 2021 | 92 | 1.260 |
Why?
|
Viral Vaccines | 3 | 2020 | 28 | 1.250 |
Why?
|
Osteomyelitis | 3 | 2013 | 17 | 1.240 |
Why?
|
Middle Aged | 47 | 2023 | 9642 | 1.210 |
Why?
|
Sexual Partners | 5 | 2016 | 308 | 1.200 |
Why?
|
Lymphocyte Count | 12 | 2022 | 46 | 1.180 |
Why?
|
Cells, Cultured | 16 | 2021 | 1442 | 1.150 |
Why?
|
Neutrophils | 4 | 2021 | 124 | 1.120 |
Why?
|
Signal Transduction | 13 | 2021 | 1802 | 1.120 |
Why?
|
Mutation | 23 | 2023 | 1023 | 1.110 |
Why?
|
Rheumatic Diseases | 2 | 2018 | 9 | 1.110 |
Why?
|
RNA | 3 | 2022 | 234 | 1.090 |
Why?
|
Anemia | 2 | 2022 | 45 | 1.080 |
Why?
|
Epigenesis, Genetic | 4 | 2016 | 198 | 1.070 |
Why?
|
Immunoglobulins | 5 | 2022 | 36 | 1.070 |
Why?
|
Antibodies, Viral | 9 | 2020 | 252 | 1.060 |
Why?
|
Neoplasms | 7 | 2022 | 1033 | 1.060 |
Why?
|
HIV Infections | 12 | 2016 | 2207 | 1.050 |
Why?
|
Lung Diseases | 2 | 2022 | 56 | 1.050 |
Why?
|
Endotoxins | 2 | 2015 | 18 | 1.040 |
Why?
|
Hypersensitivity | 6 | 2022 | 28 | 1.000 |
Why?
|
Hypersensitivity, Immediate | 2 | 2021 | 11 | 0.990 |
Why?
|
HIV Seropositivity | 5 | 2014 | 182 | 0.980 |
Why?
|
Thiazoles | 3 | 2019 | 71 | 0.980 |
Why?
|
Nephrotic Syndrome | 2 | 2022 | 9 | 0.970 |
Why?
|
Heart Defects, Congenital | 5 | 2023 | 61 | 0.960 |
Why?
|
Bronchiectasis | 3 | 2023 | 9 | 0.950 |
Why?
|
Protein Binding | 9 | 2019 | 913 | 0.950 |
Why?
|
Graft vs Host Disease | 10 | 2023 | 15 | 0.950 |
Why?
|
Arthritis | 3 | 2017 | 16 | 0.950 |
Why?
|
Cell Line | 13 | 2021 | 1289 | 0.950 |
Why?
|
Toll-Like Receptors | 7 | 2019 | 47 | 0.940 |
Why?
|
Leukemia, Myeloid, Acute | 3 | 2013 | 29 | 0.940 |
Why?
|
Genetic Testing | 7 | 2022 | 71 | 0.930 |
Why?
|
MicroRNAs | 3 | 2021 | 386 | 0.930 |
Why?
|
Micronutrients | 1 | 2023 | 42 | 0.930 |
Why?
|
T-Lymphocyte Subsets | 7 | 2020 | 84 | 0.920 |
Why?
|
Vaccination | 5 | 2019 | 259 | 0.910 |
Why?
|
Bone Marrow Diseases | 1 | 2022 | 4 | 0.900 |
Why?
|
Immunoglobulin G | 9 | 2020 | 232 | 0.890 |
Why?
|
Leukopenia | 1 | 2022 | 9 | 0.890 |
Why?
|
Complement Activation | 1 | 2022 | 13 | 0.890 |
Why?
|
Horse Diseases | 1 | 2022 | 8 | 0.890 |
Why?
|
Iron Overload | 1 | 2022 | 7 | 0.880 |
Why?
|
Lymphocytes | 6 | 2022 | 116 | 0.880 |
Why?
|
Histone Code | 2 | 2019 | 12 | 0.860 |
Why?
|
DNA Mutational Analysis | 3 | 2021 | 89 | 0.860 |
Why?
|
Respiratory Tract Infections | 5 | 2022 | 31 | 0.860 |
Why?
|
Animals | 36 | 2023 | 14307 | 0.850 |
Why?
|
B-Lymphocyte Subsets | 2 | 2013 | 16 | 0.840 |
Why?
|
Sepsis | 2 | 2021 | 76 | 0.840 |
Why?
|
Immune Tolerance | 3 | 2017 | 61 | 0.830 |
Why?
|
Patient Acceptance of Health Care | 2 | 2016 | 375 | 0.830 |
Why?
|
Keratinocytes | 3 | 2021 | 65 | 0.830 |
Why?
|
Chemokine CXCL9 | 2 | 2021 | 2 | 0.810 |
Why?
|
Keratoderma, Palmoplantar | 1 | 2021 | 1 | 0.800 |
Why?
|
Deafness | 1 | 2021 | 2 | 0.800 |
Why?
|
Chromatin Immunoprecipitation | 6 | 2018 | 71 | 0.780 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 2 | 2022 | 27 | 0.770 |
Why?
|
Prevalence | 15 | 2022 | 1425 | 0.760 |
Why?
|
Interleukin-1beta | 2 | 2020 | 66 | 0.760 |
Why?
|
Influenza A virus | 2 | 2010 | 25 | 0.750 |
Why?
|
Immunoglobulins, Intravenous | 4 | 2018 | 18 | 0.740 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 14 | 0.740 |
Why?
|
Women | 2 | 2010 | 26 | 0.740 |
Why?
|
Interleukin-1alpha | 1 | 2020 | 17 | 0.730 |
Why?
|
Chemokine CXCL10 | 1 | 2020 | 37 | 0.730 |
Why?
|
DNA-Binding Proteins | 5 | 2015 | 522 | 0.730 |
Why?
|
Arachnodactyly | 1 | 2019 | 2 | 0.730 |
Why?
|
Aged | 22 | 2022 | 6448 | 0.720 |
Why?
|
Toll-Like Receptor 2 | 1 | 2019 | 25 | 0.710 |
Why?
|
Colitis | 3 | 2021 | 64 | 0.710 |
Why?
|
Transcription Initiation Site | 2 | 2016 | 12 | 0.710 |
Why?
|
Prolactin | 1 | 2019 | 59 | 0.700 |
Why?
|
Histone Acetyltransferases | 2 | 2019 | 18 | 0.700 |
Why?
|
Receptor, erbB-2 | 2 | 2022 | 122 | 0.700 |
Why?
|
ADAM Proteins | 1 | 2018 | 15 | 0.680 |
Why?
|
Anti-Bacterial Agents | 3 | 2019 | 355 | 0.680 |
Why?
|
Diet | 4 | 2023 | 747 | 0.670 |
Why?
|
NF-kappa B | 3 | 2018 | 306 | 0.660 |
Why?
|
Cohort Studies | 14 | 2022 | 1422 | 0.660 |
Why?
|
Antineoplastic Agents | 4 | 2013 | 756 | 0.650 |
Why?
|
Prospective Studies | 10 | 2023 | 1353 | 0.650 |
Why?
|
Thinness | 1 | 2018 | 29 | 0.640 |
Why?
|
X-Linked Combined Immunodeficiency Diseases | 3 | 2019 | 3 | 0.640 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2018 | 24 | 0.640 |
Why?
|
Interferons | 5 | 2017 | 34 | 0.640 |
Why?
|
Men | 2 | 2009 | 16 | 0.640 |
Why?
|
Opportunistic Infections | 4 | 2014 | 10 | 0.640 |
Why?
|
Immunologic Memory | 4 | 2015 | 38 | 0.620 |
Why?
|
Ranidae | 2 | 2014 | 10 | 0.620 |
Why?
|
Travel | 1 | 2017 | 32 | 0.620 |
Why?
|
Positive Transcriptional Elongation Factor B | 1 | 2017 | 12 | 0.620 |
Why?
|
Complement C3 Nephritic Factor | 1 | 2017 | 1 | 0.620 |
Why?
|
Complement Pathway, Alternative | 1 | 2017 | 2 | 0.610 |
Why?
|
Serpins | 1 | 2017 | 26 | 0.610 |
Why?
|
Acetylation | 6 | 2019 | 94 | 0.610 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 2017 | 45 | 0.610 |
Why?
|
RNA, Messenger | 4 | 2018 | 1152 | 0.610 |
Why?
|
Antigen-Antibody Complex | 1 | 2016 | 19 | 0.590 |
Why?
|
Vitamin A | 2 | 2014 | 87 | 0.590 |
Why?
|
Antigens, Neoplasm | 1 | 2017 | 56 | 0.590 |
Why?
|
Epidermis | 1 | 2016 | 26 | 0.580 |
Why?
|
Transcription Factors | 3 | 2017 | 653 | 0.580 |
Why?
|
Enhancer Elements, Genetic | 2 | 2015 | 60 | 0.570 |
Why?
|
Microarray Analysis | 2 | 2018 | 61 | 0.570 |
Why?
|
Immunophenotyping | 7 | 2021 | 53 | 0.570 |
Why?
|
Enterovirus Infections | 1 | 2016 | 4 | 0.570 |
Why?
|
Treatment Outcome | 13 | 2020 | 1349 | 0.570 |
Why?
|
Somatic Hypermutation, Immunoglobulin | 1 | 2015 | 8 | 0.560 |
Why?
|
Down-Regulation | 1 | 2018 | 420 | 0.560 |
Why?
|
Mesangial Cells | 1 | 2015 | 9 | 0.550 |
Why?
|
Repressor Proteins | 4 | 2021 | 226 | 0.550 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2015 | 41 | 0.550 |
Why?
|
Adoptive Transfer | 2 | 2012 | 48 | 0.540 |
Why?
|
Lymphocyte Activation | 2 | 2015 | 222 | 0.540 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2015 | 62 | 0.540 |
Why?
|
Unsafe Sex | 2 | 2016 | 161 | 0.540 |
Why?
|
Perissodactyla | 3 | 2022 | 3 | 0.540 |
Why?
|
Interferon-alpha | 1 | 2015 | 37 | 0.540 |
Why?
|
Pelvic Inflammatory Disease | 1 | 2015 | 20 | 0.540 |
Why?
|
Cell Differentiation | 6 | 2021 | 562 | 0.530 |
Why?
|
Bufonidae | 1 | 2014 | 1 | 0.530 |
Why?
|
Gene Expression Profiling | 4 | 2021 | 600 | 0.520 |
Why?
|
Genetic Markers | 1 | 2015 | 118 | 0.520 |
Why?
|
Genetic Diseases, Inborn | 3 | 2021 | 11 | 0.520 |
Why?
|
Arthritis, Rheumatoid | 2 | 2005 | 52 | 0.520 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2016 | 37 | 0.510 |
Why?
|
Lung Diseases, Interstitial | 3 | 2023 | 11 | 0.510 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2013 | 178 | 0.510 |
Why?
|
Chemokine CCL2 | 1 | 2015 | 82 | 0.500 |
Why?
|
Vaccines, Attenuated | 3 | 2020 | 72 | 0.500 |
Why?
|
Creatinine | 4 | 2023 | 101 | 0.500 |
Why?
|
RNA Polymerase II | 3 | 2017 | 24 | 0.500 |
Why?
|
Kidney | 2 | 2023 | 322 | 0.500 |
Why?
|
United States | 22 | 2022 | 3894 | 0.500 |
Why?
|
RNA, Small Nuclear | 1 | 2014 | 9 | 0.500 |
Why?
|
Syndrome | 7 | 2023 | 72 | 0.490 |
Why?
|
Interferon-gamma | 2 | 2021 | 235 | 0.490 |
Why?
|
Education, Medical, Continuing | 1 | 2014 | 31 | 0.490 |
Why?
|
Staff Development | 1 | 2014 | 28 | 0.490 |
Why?
|
Physicians | 2 | 2014 | 148 | 0.490 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2014 | 15 | 0.490 |
Why?
|
Sirolimus | 4 | 2009 | 58 | 0.490 |
Why?
|
Flow Cytometry | 6 | 2015 | 392 | 0.490 |
Why?
|
Drug Therapy | 1 | 2013 | 18 | 0.480 |
Why?
|
Myeloid Differentiation Factor 88 | 2 | 2010 | 15 | 0.480 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 6 | 2020 | 605 | 0.470 |
Why?
|
Anxiety | 2 | 2020 | 705 | 0.470 |
Why?
|
Antigens, CD | 3 | 2014 | 116 | 0.470 |
Why?
|
Immunohistochemistry | 6 | 2021 | 859 | 0.460 |
Why?
|
Chromosomes | 3 | 2023 | 35 | 0.460 |
Why?
|
Sexually Transmitted Diseases | 1 | 2015 | 165 | 0.460 |
Why?
|
Genotype | 8 | 2022 | 641 | 0.460 |
Why?
|
Killer Cells, Natural | 4 | 2019 | 86 | 0.460 |
Why?
|
Urticaria | 2 | 2018 | 5 | 0.460 |
Why?
|
Chronic Disease | 6 | 2020 | 469 | 0.450 |
Why?
|
Thrombocytopenia | 2 | 2022 | 21 | 0.450 |
Why?
|
Abnormalities, Multiple | 3 | 2015 | 31 | 0.450 |
Why?
|
Dermatomyositis | 2 | 2002 | 6 | 0.450 |
Why?
|
Mice | 16 | 2016 | 5668 | 0.450 |
Why?
|
Immunity, Humoral | 1 | 2012 | 23 | 0.440 |
Why?
|
Antirheumatic Agents | 1 | 2012 | 33 | 0.440 |
Why?
|
Bone and Bones | 1 | 2013 | 89 | 0.440 |
Why?
|
Pneumonia | 2 | 2023 | 50 | 0.440 |
Why?
|
Hemagglutination Inhibition Tests | 4 | 2013 | 8 | 0.440 |
Why?
|
Poly I-C | 2 | 2010 | 7 | 0.430 |
Why?
|
Gene Expression | 7 | 2021 | 639 | 0.430 |
Why?
|
Wiskott-Aldrich Syndrome | 2 | 2023 | 4 | 0.430 |
Why?
|
Cross-Sectional Studies | 12 | 2023 | 2561 | 0.430 |
Why?
|
Liver | 2 | 2014 | 447 | 0.430 |
Why?
|
Transplantation Conditioning | 6 | 2020 | 7 | 0.430 |
Why?
|
Excipients | 1 | 2012 | 19 | 0.430 |
Why?
|
Quality of Life | 3 | 2023 | 459 | 0.420 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2011 | 4 | 0.420 |
Why?
|
Proline | 1 | 2012 | 37 | 0.420 |
Why?
|
Case-Control Studies | 12 | 2023 | 1056 | 0.420 |
Why?
|
Neuroblastoma | 1 | 2012 | 128 | 0.420 |
Why?
|
Organ Transplantation | 1 | 2011 | 17 | 0.420 |
Why?
|
Polymorphism, Single Nucleotide | 7 | 2015 | 638 | 0.420 |
Why?
|
Protein Transport | 3 | 2021 | 286 | 0.410 |
Why?
|
Gene Deletion | 2 | 2015 | 156 | 0.410 |
Why?
|
Genome-Wide Association Study | 7 | 2022 | 271 | 0.410 |
Why?
|
Skin | 7 | 2023 | 173 | 0.410 |
Why?
|
Polyendocrinopathies, Autoimmune | 2 | 2008 | 3 | 0.410 |
Why?
|
Systemic Inflammatory Response Syndrome | 2 | 2021 | 6 | 0.410 |
Why?
|
Apoptosis | 6 | 2016 | 1317 | 0.410 |
Why?
|
Bone Morphogenetic Protein 4 | 2 | 2021 | 7 | 0.400 |
Why?
|
Severity of Illness Index | 10 | 2022 | 608 | 0.400 |
Why?
|
Autoantigens | 2 | 2015 | 82 | 0.400 |
Why?
|
Immunosuppressive Agents | 5 | 2018 | 72 | 0.390 |
Why?
|
Recurrence | 5 | 2013 | 125 | 0.390 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 2 | 2014 | 21 | 0.390 |
Why?
|
Risk Factors | 12 | 2022 | 3414 | 0.390 |
Why?
|
Genome, Human | 1 | 2011 | 112 | 0.390 |
Why?
|
Staphylococcus aureus | 2 | 2017 | 80 | 0.390 |
Why?
|
Sarcoma | 1 | 2010 | 9 | 0.380 |
Why?
|
Orthomyxoviridae Infections | 1 | 2010 | 11 | 0.380 |
Why?
|
Multiple Myeloma | 1 | 2010 | 32 | 0.380 |
Why?
|
Stem Cell Transplantation | 1 | 2010 | 31 | 0.380 |
Why?
|
Lysosomes | 1 | 2010 | 80 | 0.380 |
Why?
|
Immune System | 1 | 2010 | 40 | 0.380 |
Why?
|
CD40 Ligand | 2 | 2021 | 6 | 0.380 |
Why?
|
Duodenum | 2 | 2017 | 12 | 0.370 |
Why?
|
Virus Diseases | 3 | 2015 | 21 | 0.370 |
Why?
|
Immunoglobulin Class Switching | 1 | 2010 | 20 | 0.370 |
Why?
|
Antigens, Viral | 2 | 2021 | 42 | 0.370 |
Why?
|
Ovarian Neoplasms | 1 | 2013 | 303 | 0.370 |
Why?
|
Self Efficacy | 5 | 2014 | 173 | 0.360 |
Why?
|
DNA Repair | 3 | 2019 | 181 | 0.360 |
Why?
|
Sinusitis | 2 | 2023 | 19 | 0.360 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2020 | 57 | 0.360 |
Why?
|
Mycoses | 2 | 2013 | 29 | 0.350 |
Why?
|
Up-Regulation | 6 | 2021 | 490 | 0.350 |
Why?
|
Antibodies, Monoclonal | 4 | 2023 | 282 | 0.350 |
Why?
|
Genetic Association Studies | 5 | 2021 | 102 | 0.340 |
Why?
|
Interleukin-23 Subunit p19 | 1 | 2008 | 2 | 0.340 |
Why?
|
Kidney Diseases | 2 | 2018 | 159 | 0.340 |
Why?
|
Germinal Center | 2 | 2018 | 10 | 0.340 |
Why?
|
Base Sequence | 4 | 2014 | 932 | 0.320 |
Why?
|
STAT1 Transcription Factor | 2 | 2018 | 26 | 0.310 |
Why?
|
Eosinophilia | 3 | 2022 | 16 | 0.310 |
Why?
|
Drug Hypersensitivity | 2 | 2017 | 6 | 0.310 |
Why?
|
Prognosis | 5 | 2021 | 707 | 0.310 |
Why?
|
Pain | 2 | 2007 | 249 | 0.310 |
Why?
|
Condoms | 3 | 2016 | 132 | 0.300 |
Why?
|
Acquired Hyperostosis Syndrome | 1 | 2007 | 2 | 0.300 |
Why?
|
Antiviral Agents | 3 | 2017 | 148 | 0.300 |
Why?
|
Tibia | 1 | 2007 | 18 | 0.300 |
Why?
|
Mannose-Binding Lectin | 2 | 2005 | 5 | 0.300 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 2006 | 4 | 0.300 |
Why?
|
Uveitis | 1 | 2006 | 5 | 0.290 |
Why?
|
Risk-Taking | 4 | 2014 | 435 | 0.290 |
Why?
|
IgA Deficiency | 2 | 2019 | 6 | 0.290 |
Why?
|
Disease Models, Animal | 4 | 2016 | 1300 | 0.290 |
Why?
|
Polyomavirus Infections | 2 | 2017 | 20 | 0.290 |
Why?
|
Iron | 2 | 2022 | 204 | 0.290 |
Why?
|
Velopharyngeal Insufficiency | 1 | 2006 | 2 | 0.290 |
Why?
|
Immunoglobulin E | 4 | 2022 | 54 | 0.290 |
Why?
|
Health Care Costs | 2 | 2017 | 69 | 0.290 |
Why?
|
Lupus Erythematosus, Cutaneous | 3 | 2016 | 4 | 0.280 |
Why?
|
Schnitzler Syndrome | 1 | 2005 | 1 | 0.280 |
Why?
|
Sneddon Syndrome | 1 | 2005 | 1 | 0.280 |
Why?
|
Probiotics | 1 | 2006 | 25 | 0.280 |
Why?
|
Aged, 80 and over | 6 | 2020 | 2333 | 0.280 |
Why?
|
Thrombosis | 1 | 2006 | 61 | 0.280 |
Why?
|
Histiocytosis, Non-Langerhans-Cell | 1 | 2005 | 2 | 0.270 |
Why?
|
Lymphoma | 2 | 2020 | 37 | 0.270 |
Why?
|
Bone Marrow Transplantation | 1 | 2005 | 15 | 0.270 |
Why?
|
Methylation | 2 | 2016 | 102 | 0.270 |
Why?
|
Binding Sites | 3 | 2015 | 597 | 0.270 |
Why?
|
Diarrhea | 2 | 2021 | 84 | 0.270 |
Why?
|
Cell Proliferation | 4 | 2022 | 1149 | 0.270 |
Why?
|
Mass Screening | 1 | 2009 | 427 | 0.270 |
Why?
|
HMGB1 Protein | 1 | 2005 | 29 | 0.270 |
Why?
|
Transplantation, Homologous | 5 | 2021 | 35 | 0.270 |
Why?
|
Nutritional Status | 2 | 2023 | 114 | 0.260 |
Why?
|
Pilot Projects | 5 | 2014 | 628 | 0.260 |
Why?
|
Hawaii | 7 | 2011 | 1878 | 0.260 |
Why?
|
Extremities | 1 | 2004 | 17 | 0.260 |
Why?
|
Nuclear Proteins | 2 | 2018 | 287 | 0.260 |
Why?
|
Staphylococcal Skin Infections | 1 | 2004 | 9 | 0.260 |
Why?
|
Edema | 1 | 2004 | 20 | 0.260 |
Why?
|
Sex Factors | 3 | 2020 | 859 | 0.260 |
Why?
|
Sexual Behavior | 2 | 2009 | 587 | 0.260 |
Why?
|
Down Syndrome | 1 | 2004 | 29 | 0.250 |
Why?
|
Muscle, Skeletal | 1 | 2007 | 257 | 0.250 |
Why?
|
Carrier Proteins | 2 | 2020 | 287 | 0.250 |
Why?
|
Hereditary Autoinflammatory Diseases | 2 | 2021 | 2 | 0.250 |
Why?
|
Fatigue | 2 | 2020 | 79 | 0.250 |
Why?
|
Empathy | 2 | 2015 | 26 | 0.250 |
Why?
|
Inflammation Mediators | 1 | 2005 | 120 | 0.250 |
Why?
|
Complement Membrane Attack Complex | 2 | 2020 | 3 | 0.250 |
Why?
|
Chondrocytes | 2 | 2021 | 15 | 0.250 |
Why?
|
Nitro Compounds | 3 | 2019 | 32 | 0.250 |
Why?
|
Immunotherapy | 2 | 2016 | 91 | 0.250 |
Why?
|
Measles-Mumps-Rubella Vaccine | 2 | 2019 | 4 | 0.240 |
Why?
|
Asthma | 4 | 2020 | 363 | 0.240 |
Why?
|
Communication | 1 | 2005 | 170 | 0.240 |
Why?
|
Ultraviolet Rays | 4 | 2023 | 116 | 0.240 |
Why?
|
North America | 4 | 2018 | 60 | 0.240 |
Why?
|
Leukocyte Disorders | 1 | 2003 | 1 | 0.240 |
Why?
|
Hematopoietic Stem Cells | 3 | 2021 | 43 | 0.240 |
Why?
|
Antigens, CD19 | 3 | 2015 | 13 | 0.240 |
Why?
|
Chromosome Disorders | 1 | 2003 | 10 | 0.240 |
Why?
|
X-Linked Inhibitor of Apoptosis Protein | 1 | 2023 | 10 | 0.240 |
Why?
|
Lizards | 1 | 2023 | 17 | 0.240 |
Why?
|
Cholecalciferol | 1 | 2023 | 19 | 0.230 |
Why?
|
Adenosine Deaminase | 2 | 2020 | 20 | 0.230 |
Why?
|
Bacterial Infections | 1 | 2003 | 44 | 0.230 |
Why?
|
Cardiac Surgical Procedures | 1 | 2023 | 48 | 0.230 |
Why?
|
Rabbits | 1 | 2023 | 278 | 0.230 |
Why?
|
Dietary Supplements | 2 | 2023 | 196 | 0.230 |
Why?
|
Abscess | 2 | 2017 | 6 | 0.230 |
Why?
|
Philadelphia | 4 | 2020 | 15 | 0.230 |
Why?
|
Medication Adherence | 3 | 2014 | 165 | 0.230 |
Why?
|
Enteritis | 1 | 2022 | 4 | 0.230 |
Why?
|
HLA-DR3 Antigen | 1 | 2002 | 1 | 0.220 |
Why?
|
Aldehyde-Lyases | 1 | 2022 | 3 | 0.220 |
Why?
|
Gastritis | 1 | 2022 | 11 | 0.220 |
Why?
|
Complement Pathway, Classical | 1 | 2022 | 2 | 0.220 |
Why?
|
Complement C4 | 1 | 2022 | 5 | 0.220 |
Why?
|
Th2 Cells | 2 | 2021 | 56 | 0.220 |
Why?
|
Edetic Acid | 1 | 2022 | 21 | 0.220 |
Why?
|
Horses | 1 | 2022 | 24 | 0.220 |
Why?
|
Ethylenediamines | 1 | 2022 | 6 | 0.220 |
Why?
|
Antibodies, Neutralizing | 5 | 2023 | 102 | 0.220 |
Why?
|
Transcriptional Activation | 2 | 2015 | 164 | 0.220 |
Why?
|
Connective Tissue Diseases | 1 | 2022 | 4 | 0.220 |
Why?
|
Dermatitis | 1 | 2022 | 8 | 0.220 |
Why?
|
Acetates | 1 | 2022 | 20 | 0.220 |
Why?
|
Frameshift Mutation | 2 | 2021 | 6 | 0.220 |
Why?
|
Iron Chelating Agents | 1 | 2022 | 21 | 0.220 |
Why?
|
Conjunctivitis | 1 | 2022 | 1 | 0.220 |
Why?
|
Proteinuria | 1 | 2022 | 48 | 0.220 |
Why?
|
Growth Disorders | 2 | 2021 | 22 | 0.220 |
Why?
|
Vaccines, Inactivated | 2 | 2013 | 14 | 0.220 |
Why?
|
Intestines | 1 | 2022 | 63 | 0.210 |
Why?
|
Receptors, Interleukin-1 | 1 | 2021 | 7 | 0.210 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2021 | 7 | 0.210 |
Why?
|
Transplantation, Autologous | 2 | 2012 | 7 | 0.210 |
Why?
|
Qa-SNARE Proteins | 1 | 2021 | 9 | 0.210 |
Why?
|
Adenoviruses, Human | 1 | 2021 | 2 | 0.210 |
Why?
|
Mutation, Missense | 2 | 2021 | 80 | 0.210 |
Why?
|
Butterflies | 1 | 2021 | 2 | 0.210 |
Why?
|
2',5'-Oligoadenylate Synthetase | 1 | 2021 | 6 | 0.210 |
Why?
|
TGF-beta Superfamily Proteins | 1 | 2021 | 1 | 0.210 |
Why?
|
Chemokines | 2 | 2017 | 89 | 0.210 |
Why?
|
Polymorphism, Genetic | 1 | 2002 | 165 | 0.200 |
Why?
|
Career Choice | 1 | 2021 | 44 | 0.200 |
Why?
|
Predictive Value of Tests | 3 | 2020 | 424 | 0.200 |
Why?
|
Histone Deacetylases | 2 | 2015 | 52 | 0.200 |
Why?
|
Osteogenesis | 1 | 2021 | 31 | 0.200 |
Why?
|
Follow-Up Studies | 6 | 2017 | 964 | 0.200 |
Why?
|
Biological Products | 1 | 2022 | 67 | 0.200 |
Why?
|
Heredity | 1 | 2020 | 5 | 0.200 |
Why?
|
Germ-Line Mutation | 1 | 2021 | 51 | 0.200 |
Why?
|
Thrombotic Microangiopathies | 1 | 2020 | 2 | 0.200 |
Why?
|
Critical Illness | 1 | 2021 | 37 | 0.200 |
Why?
|
Hyperostosis | 1 | 2020 | 1 | 0.200 |
Why?
|
Leukocytes, Mononuclear | 3 | 2013 | 224 | 0.200 |
Why?
|
Sexually Transmitted Diseases, Viral | 1 | 2020 | 11 | 0.200 |
Why?
|
Primary Health Care | 1 | 2003 | 283 | 0.200 |
Why?
|
CD4 Lymphocyte Count | 1 | 2021 | 185 | 0.200 |
Why?
|
Antigen Presentation | 1 | 2021 | 54 | 0.190 |
Why?
|
Organoids | 1 | 2021 | 20 | 0.190 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2021 | 58 | 0.190 |
Why?
|
International Cooperation | 2 | 2017 | 44 | 0.190 |
Why?
|
Wiskott-Aldrich Syndrome Protein | 1 | 2020 | 2 | 0.190 |
Why?
|
Societies, Scientific | 2 | 2017 | 8 | 0.190 |
Why?
|
Proteome | 1 | 2021 | 132 | 0.190 |
Why?
|
Dendritic Cells | 2 | 2021 | 112 | 0.190 |
Why?
|
Gastroenterology | 1 | 2020 | 8 | 0.190 |
Why?
|
Trans-Activators | 1 | 2021 | 167 | 0.190 |
Why?
|
Organ Size | 1 | 2020 | 148 | 0.190 |
Why?
|
Survivors | 1 | 2021 | 126 | 0.180 |
Why?
|
Antibiotic Prophylaxis | 1 | 2019 | 7 | 0.180 |
Why?
|
Fetus | 1 | 2020 | 103 | 0.180 |
Why?
|
Ultrasonography | 1 | 2020 | 115 | 0.180 |
Why?
|
Endothelium, Vascular | 1 | 2021 | 229 | 0.180 |
Why?
|
Mood Disorders | 1 | 2020 | 43 | 0.180 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 150 | 0.180 |
Why?
|
Interleukin-4 | 2 | 2011 | 69 | 0.180 |
Why?
|
Endotoxemia | 1 | 2019 | 5 | 0.180 |
Why?
|
Allergens | 2 | 2018 | 58 | 0.180 |
Why?
|
Fibroblasts | 2 | 2022 | 252 | 0.180 |
Why?
|
Lung | 1 | 2022 | 413 | 0.180 |
Why?
|
Receptors, Pattern Recognition | 1 | 2019 | 9 | 0.180 |
Why?
|
Homeodomain Proteins | 2 | 2022 | 128 | 0.180 |
Why?
|
Drosophila melanogaster | 1 | 2021 | 168 | 0.180 |
Why?
|
Tight Junctions | 1 | 2019 | 24 | 0.180 |
Why?
|
Psychotic Disorders | 1 | 2020 | 52 | 0.180 |
Why?
|
Interleukin-2 Receptor beta Subunit | 1 | 2019 | 6 | 0.180 |
Why?
|
Logistic Models | 3 | 2015 | 894 | 0.180 |
Why?
|
Blotting, Western | 2 | 2014 | 834 | 0.180 |
Why?
|
Longevity | 1 | 2021 | 143 | 0.180 |
Why?
|
Proto-Oncogene Proteins | 1 | 2021 | 229 | 0.180 |
Why?
|
Coronavirus Infections | 1 | 2020 | 63 | 0.180 |
Why?
|
Anti-HIV Agents | 2 | 2014 | 394 | 0.170 |
Why?
|
Brain | 2 | 2017 | 1268 | 0.170 |
Why?
|
Internet | 1 | 2020 | 204 | 0.170 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 70 | 0.170 |
Why?
|
Busulfan | 1 | 2018 | 4 | 0.170 |
Why?
|
Intestinal Mucosa | 2 | 2018 | 115 | 0.170 |
Why?
|
Skin Diseases | 1 | 2019 | 32 | 0.170 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2013 | 112 | 0.170 |
Why?
|
Poliovirus | 1 | 2018 | 5 | 0.170 |
Why?
|
CARD Signaling Adaptor Proteins | 1 | 2018 | 11 | 0.170 |
Why?
|
Guanylate Cyclase | 1 | 2018 | 17 | 0.170 |
Why?
|
Embryonic Development | 1 | 2019 | 73 | 0.170 |
Why?
|
Guanine Nucleotide Exchange Factors | 2 | 2022 | 28 | 0.170 |
Why?
|
Eosinophils | 1 | 2018 | 19 | 0.170 |
Why?
|
Pediatrics | 1 | 2019 | 66 | 0.170 |
Why?
|
Activating Transcription Factor 3 | 1 | 2018 | 3 | 0.160 |
Why?
|
Animals, Zoo | 4 | 2023 | 8 | 0.160 |
Why?
|
Gene Regulatory Networks | 1 | 2019 | 115 | 0.160 |
Why?
|
Molecular Sequence Data | 2 | 2014 | 1490 | 0.160 |
Why?
|
Models, Theoretical | 2 | 2017 | 210 | 0.160 |
Why?
|
Time Factors | 6 | 2018 | 1681 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2018 | 16 | 0.160 |
Why?
|
Chemokine CCL5 | 1 | 2018 | 38 | 0.160 |
Why?
|
Lectins, C-Type | 2 | 2015 | 35 | 0.160 |
Why?
|
Rectal Fistula | 1 | 2017 | 1 | 0.160 |
Why?
|
Mevalonate Kinase Deficiency | 1 | 2017 | 1 | 0.160 |
Why?
|
Escherichia coli | 1 | 2021 | 436 | 0.160 |
Why?
|
Minority Groups | 1 | 2023 | 537 | 0.160 |
Why?
|
Polyomavirus | 1 | 2017 | 3 | 0.160 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 1 | 2017 | 7 | 0.160 |
Why?
|
Mevalonic Acid | 1 | 2017 | 9 | 0.160 |
Why?
|
Antiparasitic Agents | 1 | 2017 | 8 | 0.160 |
Why?
|
Rectum | 1 | 2017 | 22 | 0.160 |
Why?
|
World Health Organization | 1 | 2017 | 30 | 0.160 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 1 | 2017 | 4 | 0.160 |
Why?
|
Anemia, Hemolytic | 1 | 2017 | 8 | 0.160 |
Why?
|
Esophagus | 1 | 2018 | 41 | 0.160 |
Why?
|
Food Hypersensitivity | 1 | 2017 | 3 | 0.160 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 2017 | 30 | 0.160 |
Why?
|
Centromere | 1 | 2017 | 18 | 0.160 |
Why?
|
Aspergillus fumigatus | 1 | 2017 | 10 | 0.160 |
Why?
|
Tooth | 1 | 2017 | 12 | 0.160 |
Why?
|
Otitis Media | 1 | 2017 | 2 | 0.160 |
Why?
|
Failure to Thrive | 1 | 2017 | 3 | 0.160 |
Why?
|
Bronchitis | 1 | 2017 | 5 | 0.160 |
Why?
|
Tetradecanoylphorbol Acetate | 2 | 2010 | 39 | 0.160 |
Why?
|
Cell Survival | 3 | 2017 | 818 | 0.160 |
Why?
|
Incidence | 5 | 2020 | 882 | 0.160 |
Why?
|
Phagocytosis | 1 | 2017 | 64 | 0.150 |
Why?
|
Lipodystrophy, Familial Partial | 1 | 2017 | 1 | 0.150 |
Why?
|
Dyskeratosis Congenita | 2 | 2014 | 2 | 0.150 |
Why?
|
K562 Cells | 2 | 2014 | 31 | 0.150 |
Why?
|
Cyclin-Dependent Kinase 9 | 1 | 2017 | 37 | 0.150 |
Why?
|
SEER Program | 1 | 2017 | 87 | 0.150 |
Why?
|
Forkhead Transcription Factors | 2 | 2008 | 74 | 0.150 |
Why?
|
Glomerulonephritis, Membranous | 1 | 2017 | 9 | 0.150 |
Why?
|
Lupus Vasculitis, Central Nervous System | 1 | 2016 | 1 | 0.150 |
Why?
|
Splenomegaly | 2 | 2022 | 4 | 0.150 |
Why?
|
Penicillins | 1 | 2016 | 12 | 0.150 |
Why?
|
Gene Frequency | 4 | 2017 | 155 | 0.150 |
Why?
|
Pseudomonas aeruginosa | 1 | 2017 | 57 | 0.150 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2017 | 73 | 0.150 |
Why?
|
Self Concept | 2 | 2015 | 136 | 0.150 |
Why?
|
Myeloid Cells | 1 | 2016 | 28 | 0.150 |
Why?
|
Receptors, Interferon | 1 | 2016 | 14 | 0.150 |
Why?
|
Interferon Type I | 2 | 2021 | 17 | 0.150 |
Why?
|
Developmental Disabilities | 1 | 2017 | 59 | 0.150 |
Why?
|
Magnetic Resonance Imaging | 2 | 2017 | 468 | 0.140 |
Why?
|
Genomics | 1 | 2018 | 201 | 0.140 |
Why?
|
Phenyl Ethers | 1 | 2016 | 4 | 0.140 |
Why?
|
Sequence Analysis, DNA | 3 | 2015 | 455 | 0.140 |
Why?
|
Siblings | 3 | 2019 | 16 | 0.140 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 203 | 0.140 |
Why?
|
Enterovirus | 1 | 2016 | 7 | 0.140 |
Why?
|
Fetal Blood | 1 | 2016 | 47 | 0.140 |
Why?
|
Epithelial Cells | 1 | 2019 | 366 | 0.140 |
Why?
|
Salix | 1 | 2015 | 1 | 0.140 |
Why?
|
Glomerulonephritis, Membranoproliferative | 1 | 2015 | 3 | 0.140 |
Why?
|
Animal Husbandry | 1 | 2015 | 14 | 0.140 |
Why?
|
Ambulatory Care Facilities | 1 | 2016 | 61 | 0.140 |
Why?
|
Cluster Analysis | 2 | 2020 | 188 | 0.140 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2015 | 25 | 0.140 |
Why?
|
Trichomonas vaginalis | 1 | 2015 | 7 | 0.140 |
Why?
|
International Classification of Diseases | 1 | 2015 | 18 | 0.140 |
Why?
|
Hospitals, Pediatric | 1 | 2015 | 19 | 0.140 |
Why?
|
Nutritive Value | 1 | 2015 | 28 | 0.140 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2015 | 24 | 0.140 |
Why?
|
Food Analysis | 1 | 2015 | 30 | 0.140 |
Why?
|
Virus Replication | 1 | 2017 | 261 | 0.140 |
Why?
|
Immunoglobulin M | 4 | 2020 | 81 | 0.140 |
Why?
|
Recombination, Genetic | 1 | 2015 | 90 | 0.130 |
Why?
|
Monosaccharide Transport Proteins | 1 | 2015 | 15 | 0.130 |
Why?
|
Oxidative Stress | 1 | 2021 | 874 | 0.130 |
Why?
|
Neisseria gonorrhoeae | 1 | 2015 | 21 | 0.130 |
Why?
|
BK Virus | 1 | 2015 | 5 | 0.130 |
Why?
|
RNA-Binding Protein FUS | 1 | 2015 | 5 | 0.130 |
Why?
|
Chromosomes, Human, Pair 16 | 1 | 2015 | 8 | 0.130 |
Why?
|
Bone Marrow Cells | 2 | 2014 | 75 | 0.130 |
Why?
|
Tumor Virus Infections | 1 | 2015 | 25 | 0.130 |
Why?
|
Virus Activation | 1 | 2015 | 35 | 0.130 |
Why?
|
Fluorescent Antibody Technique | 1 | 2015 | 185 | 0.130 |
Why?
|
Attitude to Health | 2 | 2009 | 311 | 0.130 |
Why?
|
Chlamydia trachomatis | 1 | 2015 | 66 | 0.130 |
Why?
|
Self Tolerance | 1 | 2014 | 4 | 0.130 |
Why?
|
Survival Rate | 4 | 2020 | 310 | 0.130 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2016 | 298 | 0.130 |
Why?
|
Consensus | 2 | 2023 | 41 | 0.130 |
Why?
|
Receptors, Interleukin-10 | 1 | 2014 | 3 | 0.130 |
Why?
|
Toll-Like Receptor 9 | 1 | 2014 | 9 | 0.130 |
Why?
|
Hemangiosarcoma | 1 | 2014 | 1 | 0.130 |
Why?
|
Liver Failure | 1 | 2014 | 7 | 0.130 |
Why?
|
Lysine | 1 | 2015 | 104 | 0.120 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 2009 | 214 | 0.120 |
Why?
|
Fatal Outcome | 3 | 2016 | 38 | 0.120 |
Why?
|
Jacobsen Distal 11q Deletion Syndrome | 1 | 2014 | 1 | 0.120 |
Why?
|
RNA Precursors | 1 | 2014 | 25 | 0.120 |
Why?
|
Calcium Channel Blockers | 1 | 2014 | 56 | 0.120 |
Why?
|
Lasers | 1 | 2014 | 62 | 0.120 |
Why?
|
Age Factors | 3 | 2014 | 1007 | 0.120 |
Why?
|
Immunoglobulin A | 4 | 2020 | 58 | 0.120 |
Why?
|
Viridans Streptococci | 1 | 2013 | 1 | 0.120 |
Why?
|
Macrophage Activation | 1 | 2014 | 52 | 0.120 |
Why?
|
Motor Neurons | 1 | 2014 | 72 | 0.120 |
Why?
|
Combined Modality Therapy | 2 | 2012 | 142 | 0.120 |
Why?
|
Europe | 4 | 2020 | 88 | 0.120 |
Why?
|
De Lange Syndrome | 1 | 2013 | 1 | 0.120 |
Why?
|
Emergency Service, Hospital | 1 | 2015 | 188 | 0.120 |
Why?
|
Heterozygote | 2 | 2021 | 91 | 0.120 |
Why?
|
Diphosphonates | 1 | 2013 | 10 | 0.120 |
Why?
|
Data Collection | 1 | 2014 | 188 | 0.120 |
Why?
|
Radionuclide Imaging | 1 | 2013 | 27 | 0.120 |
Why?
|
Streptococcal Infections | 1 | 2013 | 32 | 0.120 |
Why?
|
Superoxide Dismutase | 1 | 2014 | 149 | 0.120 |
Why?
|
Gene Knockdown Techniques | 1 | 2014 | 161 | 0.120 |
Why?
|
Piperazines | 1 | 2014 | 109 | 0.120 |
Why?
|
Pedigree | 3 | 2021 | 64 | 0.120 |
Why?
|
RNA, Small Interfering | 2 | 2018 | 391 | 0.120 |
Why?
|
Genetic Counseling | 2 | 2023 | 10 | 0.120 |
Why?
|
Qc-SNARE Proteins | 1 | 2012 | 1 | 0.110 |
Why?
|
Qb-SNARE Proteins | 1 | 2012 | 2 | 0.110 |
Why?
|
Cell Cycle Proteins | 3 | 2015 | 220 | 0.110 |
Why?
|
Drug Combinations | 2 | 2021 | 89 | 0.110 |
Why?
|
Demography | 2 | 2012 | 167 | 0.110 |
Why?
|
Substance-Related Disorders | 3 | 2014 | 685 | 0.110 |
Why?
|
Lymphocyte Depletion | 1 | 2012 | 13 | 0.110 |
Why?
|
RNA Interference | 1 | 2014 | 225 | 0.110 |
Why?
|
Skin Tests | 2 | 2016 | 13 | 0.110 |
Why?
|
Iron Metabolism Disorders | 1 | 2012 | 2 | 0.110 |
Why?
|
Immunotherapy, Adoptive | 1 | 2012 | 13 | 0.110 |
Why?
|
Longitudinal Studies | 3 | 2023 | 841 | 0.110 |
Why?
|
Homozygote | 2 | 2019 | 75 | 0.110 |
Why?
|
Depression | 2 | 2017 | 664 | 0.110 |
Why?
|
Computational Biology | 1 | 2015 | 275 | 0.110 |
Why?
|
Comorbidity | 3 | 2020 | 606 | 0.110 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 106 | 0.110 |
Why?
|
Bronchiolitis Obliterans | 1 | 2012 | 2 | 0.110 |
Why?
|
Anti-Retroviral Agents | 1 | 2013 | 139 | 0.110 |
Why?
|
DNA Methylation | 1 | 2015 | 301 | 0.110 |
Why?
|
Munc18 Proteins | 1 | 2012 | 2 | 0.110 |
Why?
|
Actins | 1 | 2013 | 142 | 0.110 |
Why?
|
Social Behavior | 1 | 2013 | 124 | 0.110 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2012 | 22 | 0.110 |
Why?
|
Pneumocystis carinii | 1 | 2011 | 2 | 0.110 |
Why?
|
Lung Transplantation | 1 | 2012 | 19 | 0.110 |
Why?
|
Linear Models | 1 | 2012 | 253 | 0.100 |
Why?
|
Antigens, Bacterial | 1 | 2012 | 129 | 0.100 |
Why?
|
Immunization, Passive | 2 | 2022 | 18 | 0.100 |
Why?
|
Drug Stability | 1 | 2012 | 110 | 0.100 |
Why?
|
Neuroprotective Agents | 1 | 2014 | 231 | 0.100 |
Why?
|
Liver Neoplasms | 1 | 2014 | 195 | 0.100 |
Why?
|
Leukocyte Count | 2 | 2019 | 74 | 0.100 |
Why?
|
DNA | 2 | 2005 | 549 | 0.100 |
Why?
|
Nitriles | 2 | 2021 | 66 | 0.100 |
Why?
|
Analysis of Variance | 2 | 2009 | 528 | 0.100 |
Why?
|
RNA, Double-Stranded | 1 | 2010 | 23 | 0.100 |
Why?
|
Pyrazoles | 2 | 2021 | 80 | 0.100 |
Why?
|
Vitamin A Deficiency | 1 | 2010 | 14 | 0.100 |
Why?
|
Washington | 1 | 2010 | 28 | 0.100 |
Why?
|
Interleukin-1 Receptor-Associated Kinases | 1 | 2010 | 6 | 0.100 |
Why?
|
Homeostasis | 3 | 2014 | 172 | 0.100 |
Why?
|
Aging | 1 | 2015 | 639 | 0.100 |
Why?
|
Transgenes | 1 | 2010 | 57 | 0.100 |
Why?
|
Endosomes | 1 | 2010 | 34 | 0.100 |
Why?
|
Plasma Cell Granuloma, Pulmonary | 1 | 2010 | 1 | 0.090 |
Why?
|
NIH 3T3 Cells | 1 | 2010 | 60 | 0.090 |
Why?
|
Pseudomonas Infections | 1 | 2010 | 18 | 0.090 |
Why?
|
Pyrimidines | 2 | 2021 | 112 | 0.090 |
Why?
|
Meningitis | 1 | 2010 | 8 | 0.090 |
Why?
|
Disease Management | 2 | 2021 | 61 | 0.090 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2011 | 184 | 0.090 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2011 | 146 | 0.090 |
Why?
|
Cell Separation | 1 | 2010 | 91 | 0.090 |
Why?
|
Hematologic Neoplasms | 1 | 2010 | 15 | 0.090 |
Why?
|
Nursing Assessment | 1 | 2009 | 7 | 0.090 |
Why?
|
Nursing Methodology Research | 1 | 2009 | 14 | 0.090 |
Why?
|
Psychological Theory | 1 | 2009 | 23 | 0.090 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2011 | 180 | 0.090 |
Why?
|
Leukemia | 1 | 2010 | 54 | 0.090 |
Why?
|
Natural Cytotoxicity Triggering Receptor 1 | 1 | 2009 | 1 | 0.090 |
Why?
|
Choanal Atresia | 1 | 2009 | 1 | 0.090 |
Why?
|
Coloboma | 1 | 2009 | 1 | 0.090 |
Why?
|
Facial Nerve Diseases | 1 | 2009 | 1 | 0.090 |
Why?
|
Tracheoesophageal Fistula | 1 | 2009 | 2 | 0.090 |
Why?
|
Spleen | 3 | 2015 | 192 | 0.090 |
Why?
|
Transfection | 1 | 2010 | 496 | 0.090 |
Why?
|
Interferon Regulatory Factors | 1 | 2009 | 15 | 0.090 |
Why?
|
Educational Status | 2 | 2014 | 295 | 0.090 |
Why?
|
Self Care | 1 | 2011 | 150 | 0.090 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2009 | 1 | 0.090 |
Why?
|
Models, Psychological | 1 | 2009 | 120 | 0.090 |
Why?
|
Community Health Services | 1 | 2011 | 175 | 0.090 |
Why?
|
Antibody Formation | 1 | 2009 | 73 | 0.090 |
Why?
|
Phosphoproteins | 1 | 2010 | 154 | 0.090 |
Why?
|
Adrenal Cortex Hormones | 2 | 2005 | 48 | 0.090 |
Why?
|
DNA Helicases | 1 | 2009 | 40 | 0.090 |
Why?
|
Phylogeny | 2 | 2022 | 612 | 0.080 |
Why?
|
Vero Cells | 2 | 2019 | 90 | 0.080 |
Why?
|
Duodenitis | 1 | 2008 | 2 | 0.080 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 2008 | 84 | 0.080 |
Why?
|
Social Class | 1 | 2010 | 228 | 0.080 |
Why?
|
Proteins | 1 | 2011 | 352 | 0.080 |
Why?
|
Biopsy | 2 | 2019 | 151 | 0.080 |
Why?
|
Activating Transcription Factors | 1 | 2008 | 4 | 0.080 |
Why?
|
Immunocompromised Host | 1 | 2008 | 21 | 0.080 |
Why?
|
Nicotine | 1 | 2010 | 238 | 0.080 |
Why?
|
Encephalitis, Herpes Simplex | 1 | 2007 | 2 | 0.080 |
Why?
|
Gene Expression Regulation, Developmental | 2 | 2021 | 283 | 0.080 |
Why?
|
Cell Membrane | 1 | 2010 | 360 | 0.080 |
Why?
|
Transcription Factor TFIID | 1 | 2007 | 2 | 0.080 |
Why?
|
TATA-Binding Protein Associated Factors | 1 | 2007 | 2 | 0.080 |
Why?
|
Cell Polarity | 1 | 2008 | 53 | 0.080 |
Why?
|
DNA Primers | 1 | 2008 | 269 | 0.080 |
Why?
|
Chromosomes, Human, X | 1 | 2007 | 14 | 0.080 |
Why?
|
Synovial Fluid | 2 | 2018 | 4 | 0.080 |
Why?
|
Malabsorption Syndromes | 1 | 2007 | 3 | 0.080 |
Why?
|
Phosphorylation | 1 | 2010 | 878 | 0.080 |
Why?
|
Cell Line, Tumor | 1 | 2014 | 2128 | 0.080 |
Why?
|
Protein-Losing Enteropathies | 1 | 2007 | 2 | 0.080 |
Why?
|
Anti-Inflammatory Agents | 2 | 2005 | 137 | 0.080 |
Why?
|
Photosensitivity Disorders | 1 | 2006 | 3 | 0.080 |
Why?
|
Socioeconomic Factors | 2 | 2014 | 1003 | 0.070 |
Why?
|
Membrane Transport Proteins | 1 | 2007 | 88 | 0.070 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2007 | 89 | 0.070 |
Why?
|
Gene Rearrangement, B-Lymphocyte | 1 | 2006 | 4 | 0.070 |
Why?
|
Low Back Pain | 1 | 1998 | 86 | 0.070 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2007 | 121 | 0.070 |
Why?
|
Enterocolitis, Pseudomembranous | 1 | 2006 | 7 | 0.070 |
Why?
|
MAP Kinase Signaling System | 1 | 2008 | 162 | 0.070 |
Why?
|
Models, Genetic | 1 | 2007 | 149 | 0.070 |
Why?
|
Skin Diseases, Vascular | 1 | 2005 | 4 | 0.070 |
Why?
|
Blood Coagulation Disorders | 1 | 2005 | 6 | 0.070 |
Why?
|
Raynaud Disease | 1 | 2005 | 10 | 0.070 |
Why?
|
Expert Testimony | 2 | 2015 | 5 | 0.070 |
Why?
|
Sexual Abstinence | 1 | 2005 | 8 | 0.070 |
Why?
|
Proto-Oncogene Protein c-ets-1 | 1 | 2005 | 8 | 0.070 |
Why?
|
Granuloma, Respiratory Tract | 1 | 2005 | 1 | 0.070 |
Why?
|
Liver Abscess | 1 | 2005 | 3 | 0.070 |
Why?
|
Nurse's Role | 1 | 2005 | 31 | 0.070 |
Why?
|
Interleukin-2 | 2 | 2019 | 87 | 0.070 |
Why?
|
Subcellular Fractions | 1 | 2005 | 72 | 0.070 |
Why?
|
Eczema | 1 | 2005 | 4 | 0.070 |
Why?
|
Patient Education as Topic | 2 | 2020 | 207 | 0.070 |
Why?
|
Stereotyping | 1 | 2005 | 40 | 0.070 |
Why?
|
Rhinitis, Allergic, Perennial | 1 | 2005 | 5 | 0.070 |
Why?
|
Leukotrienes | 1 | 2005 | 4 | 0.070 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2005 | 15 | 0.070 |
Why?
|
Dental Care for Chronically Ill | 1 | 2005 | 3 | 0.070 |
Why?
|
HLA Antigens | 1 | 2005 | 19 | 0.070 |
Why?
|
Craniofacial Abnormalities | 1 | 2005 | 21 | 0.070 |
Why?
|
Safe Sex | 1 | 2005 | 73 | 0.070 |
Why?
|
Major Histocompatibility Complex | 1 | 2005 | 21 | 0.070 |
Why?
|
Interleukins | 1 | 2005 | 28 | 0.070 |
Why?
|
Hematologic Diseases | 1 | 2005 | 14 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2008 | 984 | 0.070 |
Why?
|
Nerve Tissue Proteins | 1 | 2007 | 338 | 0.070 |
Why?
|
Mupirocin | 1 | 2004 | 1 | 0.070 |
Why?
|
Methicillin Resistance | 1 | 2004 | 12 | 0.060 |
Why?
|
Orthomyxoviridae | 1 | 2004 | 5 | 0.060 |
Why?
|
Abdominal Pain | 1 | 2004 | 24 | 0.060 |
Why?
|
Kidney Glomerulus | 1 | 2005 | 80 | 0.060 |
Why?
|
Mast Cells | 1 | 2005 | 77 | 0.060 |
Why?
|
Administration, Intranasal | 1 | 2004 | 77 | 0.060 |
Why?
|
Tumor Suppressor Proteins | 1 | 2006 | 184 | 0.060 |
Why?
|
Stem Cells | 2 | 2021 | 132 | 0.060 |
Why?
|
Periodontitis | 1 | 2005 | 52 | 0.060 |
Why?
|
Adaptation, Physiological | 1 | 2005 | 106 | 0.060 |
Why?
|
Ataxia Telangiectasia | 2 | 2019 | 6 | 0.060 |
Why?
|
Kinetics | 1 | 2005 | 650 | 0.060 |
Why?
|
Chickenpox Vaccine | 1 | 2003 | 2 | 0.060 |
Why?
|
Chickenpox | 1 | 2003 | 6 | 0.060 |
Why?
|
Interpersonal Relations | 1 | 2005 | 198 | 0.060 |
Why?
|
Mice, Inbred BALB C | 1 | 2005 | 649 | 0.060 |
Why?
|
DNA Copy Number Variations | 2 | 2015 | 27 | 0.060 |
Why?
|
Data Mining | 1 | 2023 | 21 | 0.060 |
Why?
|
DNA Damage | 1 | 2006 | 341 | 0.060 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2003 | 25 | 0.060 |
Why?
|
Research Design | 1 | 2005 | 292 | 0.060 |
Why?
|
Cardiopulmonary Bypass | 1 | 2023 | 22 | 0.060 |
Why?
|
U937 Cells | 1 | 2003 | 27 | 0.060 |
Why?
|
Disease-Free Survival | 2 | 2017 | 114 | 0.060 |
Why?
|
Safety | 1 | 2003 | 48 | 0.060 |
Why?
|
Butyrates | 1 | 2003 | 31 | 0.060 |
Why?
|
Telomere | 1 | 2003 | 51 | 0.060 |
Why?
|
Mice, Inbred MRL lpr | 1 | 2002 | 1 | 0.060 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2003 | 34 | 0.060 |
Why?
|
HIV Seronegativity | 1 | 2003 | 38 | 0.060 |
Why?
|
Social Support | 1 | 2005 | 356 | 0.060 |
Why?
|
Lymphocyte Subsets | 1 | 2002 | 19 | 0.060 |
Why?
|
Nervous System Malformations | 1 | 2022 | 2 | 0.060 |
Why?
|
Autoimmune Diseases of the Nervous System | 1 | 2022 | 2 | 0.060 |
Why?
|
Chromium | 1 | 2022 | 27 | 0.060 |
Why?
|
Immunocompetence | 1 | 2022 | 8 | 0.060 |
Why?
|
Databases, Factual | 2 | 2017 | 288 | 0.050 |
Why?
|
Antibodies | 1 | 2002 | 135 | 0.050 |
Why?
|
Steroids | 1 | 2022 | 43 | 0.050 |
Why?
|
Cell Culture Techniques | 2 | 2018 | 136 | 0.050 |
Why?
|
Group II Phospholipases A2 | 1 | 2021 | 3 | 0.050 |
Why?
|
Stroke | 1 | 2005 | 274 | 0.050 |
Why?
|
Postoperative Complications | 1 | 2023 | 206 | 0.050 |
Why?
|
Parents | 1 | 2005 | 288 | 0.050 |
Why?
|
Motivation | 1 | 2005 | 415 | 0.050 |
Why?
|
Proportional Hazards Models | 1 | 2023 | 423 | 0.050 |
Why?
|
Morbidity | 1 | 2022 | 94 | 0.050 |
Why?
|
STAT3 Transcription Factor | 1 | 2022 | 80 | 0.050 |
Why?
|
Pennsylvania | 1 | 2021 | 41 | 0.050 |
Why?
|
Vascular Diseases | 1 | 2021 | 30 | 0.050 |
Why?
|
Lymphopoiesis | 1 | 2021 | 1 | 0.050 |
Why?
|
Interleukin-10 | 1 | 2021 | 69 | 0.050 |
Why?
|
Enzyme Assays | 1 | 2021 | 11 | 0.050 |
Why?
|
Precursor Cells, B-Lymphoid | 1 | 2021 | 3 | 0.050 |
Why?
|
Culture Media, Conditioned | 1 | 2021 | 44 | 0.050 |
Why?
|
Animal Feed | 2 | 2012 | 42 | 0.050 |
Why?
|
Hematopoiesis | 1 | 2021 | 30 | 0.050 |
Why?
|
Gene Knockout Techniques | 1 | 2021 | 46 | 0.050 |
Why?
|
Inheritance Patterns | 1 | 2021 | 7 | 0.050 |
Why?
|
Endoribonucleases | 1 | 2021 | 23 | 0.050 |
Why?
|
Vitamin D | 1 | 2023 | 176 | 0.050 |
Why?
|
Genes, X-Linked | 1 | 2021 | 8 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2003 | 396 | 0.050 |
Why?
|
T-Box Domain Proteins | 1 | 2020 | 7 | 0.050 |
Why?
|
Managed Care Programs | 1 | 2021 | 35 | 0.050 |
Why?
|
Larva | 1 | 2021 | 117 | 0.050 |
Why?
|
Immunity, Innate | 1 | 2021 | 135 | 0.050 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2021 | 57 | 0.050 |
Why?
|
Myeloablative Agonists | 1 | 2020 | 1 | 0.050 |
Why?
|
Pathology, Molecular | 1 | 2020 | 9 | 0.050 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2021 | 69 | 0.050 |
Why?
|
Species Specificity | 1 | 2021 | 233 | 0.050 |
Why?
|
Africa | 1 | 2020 | 62 | 0.050 |
Why?
|
Feces | 1 | 2021 | 110 | 0.050 |
Why?
|
Lymphocytosis | 1 | 2020 | 2 | 0.050 |
Why?
|
Neurodegenerative Diseases | 1 | 2002 | 119 | 0.050 |
Why?
|
Pseudolymphoma | 1 | 2020 | 4 | 0.050 |
Why?
|
Asia | 1 | 2020 | 74 | 0.050 |
Why?
|
Treatment Failure | 1 | 2020 | 65 | 0.050 |
Why?
|
Molecular Dynamics Simulation | 1 | 2021 | 117 | 0.050 |
Why?
|
Chromosome Mapping | 2 | 2012 | 159 | 0.050 |
Why?
|
Alleles | 1 | 2021 | 284 | 0.050 |
Why?
|
Cell Communication | 1 | 2020 | 93 | 0.050 |
Why?
|
Homosexuality, Male | 1 | 2005 | 438 | 0.050 |
Why?
|
Virus Shedding | 1 | 2019 | 9 | 0.050 |
Why?
|
Transplantation Chimera | 1 | 2019 | 7 | 0.050 |
Why?
|
Collagen | 1 | 2020 | 162 | 0.050 |
Why?
|
Societies, Medical | 1 | 2020 | 62 | 0.050 |
Why?
|
Recombinant Proteins | 1 | 2021 | 485 | 0.050 |
Why?
|
Cell Compartmentation | 1 | 2019 | 12 | 0.040 |
Why?
|
Proteomics | 1 | 2021 | 302 | 0.040 |
Why?
|
Interleukin-15 | 1 | 2019 | 13 | 0.040 |
Why?
|
Nijmegen Breakage Syndrome | 1 | 2019 | 1 | 0.040 |
Why?
|
Hirschsprung Disease | 1 | 2019 | 3 | 0.040 |
Why?
|
Osteochondrodysplasias | 1 | 2019 | 2 | 0.040 |
Why?
|
RNA, Viral | 1 | 2020 | 287 | 0.040 |
Why?
|
Cytomegalovirus Infections | 1 | 2019 | 22 | 0.040 |
Why?
|
Hair | 1 | 2019 | 20 | 0.040 |
Why?
|
Viral Envelope Proteins | 1 | 2019 | 77 | 0.040 |
Why?
|
Genome, Viral | 1 | 2019 | 103 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 187 | 0.040 |
Why?
|
Reproducibility of Results | 2 | 2015 | 901 | 0.040 |
Why?
|
Viral Load | 2 | 2015 | 300 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2022 | 486 | 0.040 |
Why?
|
Tissue Distribution | 1 | 2019 | 197 | 0.040 |
Why?
|
Insurance Claim Review | 1 | 2018 | 24 | 0.040 |
Why?
|
Hyperplasia | 1 | 2018 | 38 | 0.040 |
Why?
|
Immunoglobulin Isotypes | 1 | 2018 | 16 | 0.040 |
Why?
|
Remission Induction | 1 | 2017 | 18 | 0.040 |
Why?
|
Gastrointestinal Diseases | 1 | 2018 | 41 | 0.040 |
Why?
|
Quebec | 1 | 2017 | 2 | 0.040 |
Why?
|
Immunization | 1 | 2018 | 90 | 0.040 |
Why?
|
Medical History Taking | 1 | 2017 | 33 | 0.040 |
Why?
|
Segmental Duplications, Genomic | 1 | 2017 | 1 | 0.040 |
Why?
|
Inhibitory Concentration 50 | 1 | 2017 | 81 | 0.040 |
Why?
|
Epilepsy | 1 | 2017 | 41 | 0.040 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2017 | 49 | 0.040 |
Why?
|
Tissue Donors | 1 | 2017 | 43 | 0.040 |
Why?
|
Face | 1 | 2017 | 49 | 0.040 |
Why?
|
Mortality | 1 | 2018 | 150 | 0.040 |
Why?
|
Exanthema | 1 | 2016 | 9 | 0.040 |
Why?
|
Cord Blood Stem Cell Transplantation | 1 | 2016 | 3 | 0.040 |
Why?
|
Survival Analysis | 1 | 2017 | 322 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2018 | 555 | 0.040 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 445 | 0.040 |
Why?
|
Starfish | 1 | 1975 | 2 | 0.040 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2017 | 166 | 0.040 |
Why?
|
Digestive System | 1 | 1975 | 19 | 0.040 |
Why?
|
Carbohydrate Metabolism | 1 | 1975 | 20 | 0.030 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2015 | 4 | 0.030 |
Why?
|
DEAD-box RNA Helicases | 1 | 2015 | 11 | 0.030 |
Why?
|
Digitoxin | 1 | 1975 | 7 | 0.030 |
Why?
|
Interleukin-10 Receptor alpha Subunit | 1 | 2015 | 1 | 0.030 |
Why?
|
Antibody Specificity | 1 | 2015 | 75 | 0.030 |
Why?
|
Mice, Inbred Strains | 1 | 2015 | 117 | 0.030 |
Why?
|
Germany | 1 | 2015 | 21 | 0.030 |
Why?
|
Models, Molecular | 1 | 2019 | 751 | 0.030 |
Why?
|
Patient Care Team | 1 | 2015 | 44 | 0.030 |
Why?
|
Evidence-Based Medicine | 1 | 2015 | 92 | 0.030 |
Why?
|
Cystitis | 1 | 2015 | 6 | 0.030 |
Why?
|
Disease Progression | 1 | 2018 | 580 | 0.030 |
Why?
|
Hematuria | 1 | 2015 | 3 | 0.030 |
Why?
|
Microsomes, Liver | 1 | 1975 | 69 | 0.030 |
Why?
|
Namibia | 1 | 2015 | 1 | 0.030 |
Why?
|
Quantitative Trait Loci | 1 | 2015 | 68 | 0.030 |
Why?
|
Thailand | 1 | 2015 | 48 | 0.030 |
Why?
|
Seroepidemiologic Studies | 1 | 2015 | 67 | 0.030 |
Why?
|
Ovary | 1 | 1975 | 101 | 0.030 |
Why?
|
Linkage Disequilibrium | 1 | 2015 | 58 | 0.030 |
Why?
|
Plant Leaves | 1 | 2015 | 110 | 0.030 |
Why?
|
Internationality | 1 | 2015 | 29 | 0.030 |
Why?
|
Viremia | 1 | 2015 | 40 | 0.030 |
Why?
|
Graft Survival | 1 | 2015 | 34 | 0.030 |
Why?
|
Genetic Loci | 1 | 2015 | 70 | 0.030 |
Why?
|
Fatty Acids | 1 | 1975 | 118 | 0.030 |
Why?
|
Retreatment | 1 | 2014 | 8 | 0.030 |
Why?
|
Canada | 1 | 2015 | 121 | 0.030 |
Why?
|
Mannose-Binding Lectins | 1 | 2014 | 14 | 0.030 |
Why?
|
Testis | 1 | 1975 | 185 | 0.030 |
Why?
|
Risk | 1 | 2015 | 256 | 0.030 |
Why?
|
Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2014 | 4 | 0.030 |
Why?
|
China | 1 | 2015 | 178 | 0.030 |
Why?
|
Inclusion Bodies | 1 | 2014 | 33 | 0.030 |
Why?
|
Receptors, IgG | 1 | 2014 | 48 | 0.030 |
Why?
|
Amyotrophic Lateral Sclerosis | 1 | 2014 | 45 | 0.030 |
Why?
|
Gene Transfer Techniques | 1 | 2014 | 43 | 0.030 |
Why?
|
Cause of Death | 1 | 2015 | 154 | 0.030 |
Why?
|
Aminoglycosides | 1 | 2013 | 6 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2014 | 62 | 0.030 |
Why?
|
Spinal Cord | 1 | 2014 | 85 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2014 | 44 | 0.030 |
Why?
|
Psychological Tests | 1 | 2014 | 52 | 0.030 |
Why?
|
Models, Animal | 1 | 2014 | 131 | 0.030 |
Why?
|
Culture | 1 | 2015 | 162 | 0.030 |
Why?
|
NFATC Transcription Factors | 1 | 2013 | 6 | 0.030 |
Why?
|
Receptors, Cell Surface | 1 | 2014 | 135 | 0.030 |
Why?
|
Immunologic Tests | 1 | 2013 | 11 | 0.030 |
Why?
|
Perception | 1 | 2015 | 183 | 0.030 |
Why?
|
Crime | 1 | 2013 | 26 | 0.030 |
Why?
|
Odds Ratio | 1 | 2015 | 517 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2014 | 164 | 0.030 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2013 | 52 | 0.030 |
Why?
|
Phlebotomy | 1 | 2012 | 4 | 0.030 |
Why?
|
Regression Analysis | 1 | 2014 | 429 | 0.030 |
Why?
|
Needs Assessment | 1 | 2014 | 159 | 0.030 |
Why?
|
Twins, Dizygotic | 1 | 2012 | 8 | 0.030 |
Why?
|
Chelating Agents | 1 | 2012 | 53 | 0.030 |
Why?
|
Ferritins | 1 | 2012 | 54 | 0.030 |
Why?
|
Calcium | 1 | 2014 | 445 | 0.020 |
Why?
|
Risk Assessment | 1 | 2014 | 727 | 0.020 |
Why?
|
Animal Nutritional Physiological Phenomena | 1 | 2010 | 9 | 0.020 |
Why?
|
Administration, Topical | 1 | 2010 | 39 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2011 | 63 | 0.020 |
Why?
|
Mitochondria | 1 | 2014 | 454 | 0.020 |
Why?
|
Cultural Characteristics | 1 | 2011 | 119 | 0.020 |
Why?
|
Administration, Oral | 1 | 2010 | 212 | 0.020 |
Why?
|
Radiography | 1 | 2009 | 75 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2008 | 30 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2009 | 145 | 0.020 |
Why?
|
Education | 1 | 2008 | 48 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2009 | 79 | 0.020 |
Why?
|
Body Weight | 1 | 2010 | 404 | 0.020 |
Why?
|
Work | 1 | 1998 | 6 | 0.020 |
Why?
|
France | 1 | 1998 | 17 | 0.020 |
Why?
|
Algorithms | 1 | 2011 | 435 | 0.020 |
Why?
|
Social Adjustment | 1 | 1998 | 26 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 1998 | 51 | 0.020 |
Why?
|
Leisure Activities | 1 | 1998 | 31 | 0.020 |
Why?
|
Puerto Rico | 1 | 2012 | 1352 | 0.020 |
Why?
|
Analgesics | 1 | 1998 | 56 | 0.020 |
Why?
|
Intestine, Large | 1 | 2007 | 4 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 1998 | 104 | 0.020 |
Why?
|
Endoscopy | 1 | 2007 | 15 | 0.020 |
Why?
|
Mucous Membrane | 1 | 2007 | 34 | 0.020 |
Why?
|
Skin Physiological Phenomena | 1 | 2006 | 11 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2006 | 32 | 0.020 |
Why?
|
Chloroquine | 1 | 1976 | 19 | 0.020 |
Why?
|
Chromosome Breakage | 1 | 2006 | 14 | 0.020 |
Why?
|
Mice, Inbred CBA | 1 | 2006 | 32 | 0.020 |
Why?
|
Mycophenolic Acid | 1 | 2006 | 7 | 0.020 |
Why?
|
Lymphoid Tissue | 1 | 2006 | 17 | 0.020 |
Why?
|
Antibodies, Antinuclear | 1 | 2006 | 20 | 0.020 |
Why?
|
Plasmodium berghei | 1 | 1976 | 29 | 0.020 |
Why?
|
Mice, Mutant Strains | 1 | 2006 | 78 | 0.020 |
Why?
|
Biomedical Research | 1 | 2011 | 371 | 0.020 |
Why?
|
Bicarbonates | 1 | 1976 | 12 | 0.020 |
Why?
|
Albumins | 1 | 1976 | 24 | 0.020 |
Why?
|
Antimalarials | 1 | 1976 | 48 | 0.020 |
Why?
|
Protein Kinases | 1 | 2006 | 91 | 0.020 |
Why?
|
Sodium | 1 | 1976 | 101 | 0.020 |
Why?
|
Ear | 1 | 2005 | 7 | 0.020 |
Why?
|
Acidosis | 1 | 1976 | 49 | 0.020 |
Why?
|
Karyotyping | 1 | 2005 | 46 | 0.020 |
Why?
|
Hypophosphatasia | 1 | 2005 | 1 | 0.020 |
Why?
|
Papillon-Lefevre Disease | 1 | 2005 | 1 | 0.020 |
Why?
|
Ehlers-Danlos Syndrome | 1 | 2005 | 5 | 0.020 |
Why?
|
Eikenella corrodens | 1 | 1975 | 2 | 0.020 |
Why?
|
Infant, Premature, Diseases | 1 | 1976 | 63 | 0.020 |
Why?
|
Bacteroides | 1 | 1975 | 8 | 0.020 |
Why?
|
Hematologic Tests | 1 | 2004 | 6 | 0.020 |
Why?
|
Lymphatic Diseases | 1 | 2004 | 7 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2005 | 91 | 0.020 |
Why?
|
Needle Sharing | 1 | 2003 | 10 | 0.010 |
Why?
|
Th1 Cells | 1 | 2003 | 87 | 0.010 |
Why?
|
Immunity, Cellular | 1 | 2003 | 68 | 0.010 |
Why?
|
Communicable Diseases | 1 | 2002 | 42 | 0.010 |
Why?
|
Digitoxigenin | 1 | 1975 | 4 | 0.010 |
Why?
|
Periodicity | 1 | 1975 | 33 | 0.010 |
Why?
|
Hydroxylation | 1 | 1975 | 14 | 0.010 |
Why?
|
NADP | 1 | 1975 | 24 | 0.010 |
Why?
|
Chromatography, Thin Layer | 1 | 1975 | 37 | 0.010 |
Why?
|
Organ Specificity | 1 | 1975 | 123 | 0.010 |
Why?
|
Reproduction | 1 | 1975 | 63 | 0.010 |
Why?
|
Rats | 1 | 1975 | 3261 | 0.010 |
Why?
|
Cytoplasmic Granules | 1 | 1976 | 8 | 0.000 |
Why?
|
Pigments, Biological | 1 | 1976 | 10 | 0.000 |
Why?
|
Vacuoles | 1 | 1976 | 22 | 0.000 |
Why?
|
Quinine | 1 | 1976 | 10 | 0.000 |
Why?
|
Phenanthrenes | 1 | 1976 | 16 | 0.000 |
Why?
|
Infusions, Parenteral | 1 | 1976 | 12 | 0.000 |
Why?
|
Piperidines | 1 | 1976 | 76 | 0.000 |
Why?
|
Quinolines | 1 | 1976 | 60 | 0.000 |
Why?
|
Respiratory Distress Syndrome, Newborn | 1 | 1976 | 19 | 0.000 |
Why?
|
Malaria | 1 | 1976 | 68 | 0.000 |
Why?
|
Erythrocytes | 1 | 1976 | 107 | 0.000 |
Why?
|
Carbon Dioxide | 1 | 1976 | 78 | 0.000 |
Why?
|
Injections, Intramuscular | 1 | 1975 | 20 | 0.000 |
Why?
|
Leg | 1 | 1975 | 20 | 0.000 |
Why?
|
Suspensions | 1 | 1975 | 42 | 0.000 |
Why?
|
Streptococcus pneumoniae | 1 | 1975 | 28 | 0.000 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1976 | 342 | 0.000 |
Why?
|
Cerebral Hemorrhage | 1 | 1976 | 103 | 0.000 |
Why?
|
Heart | 1 | 1975 | 178 | 0.000 |
Why?
|